(Q39248784)

10 September 2017

title

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). (English)

1 reference

10 September 2017

Mark Bishton

2

0 references

Simon Harrison

object named as

Simon J Harrison

1

0 references

Ricky W Johnstone

object named as

Ricky W Johnstone

6

0 references

Susan E Bates

3

object named as

Susan E Bates

1 reference

10 September 2017

5

Richard L Piekarz

1 reference

10 September 2017

Steven Grant

4

1 reference

10 September 2017

Yun Dai

7

1 reference

10 September 2017

Becki Lee

8

1 reference

10 September 2017

Maria E Araujo

9

1 reference

10 September 2017

H Miles Prince

10

1 reference

10 September 2017

publication date

1 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

4

1 reference

10 September 2017

issue

5

1 reference

10 September 2017

page(s)

571-589

1 reference

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

10 September 2017

cites work

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Worms gang up on bacteria

21 January 2018

1 reference

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

21 January 2018

1 reference

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

21 January 2018

1 reference

HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage

21 January 2018

1 reference

MBD3 and HDAC1, two components of the NuRD complex, are localized at Aurora-A-positive centrosomes in M phase

21 January 2018

1 reference

Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity

21 January 2018

1 reference

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells

21 January 2018

1 reference

Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates

21 January 2018

1 reference

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

21 January 2018

1 reference

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway

21 January 2018

1 reference

Function and molecular mechanism of acetylation in autophagy regulation

21 January 2018

1 reference

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

21 January 2018

1 reference

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.

21 January 2018

1 reference

Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells

21 January 2018

1 reference

An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner

21 January 2018

1 reference

Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.

21 January 2018

1 reference

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

21 January 2018

1 reference

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

21 January 2018

1 reference

The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.

21 January 2018

1 reference

Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6

21 January 2018

2 references

21 January 2018

12 December 2020

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

21 January 2018

1 reference

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

21 January 2018

1 reference

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells

21 January 2018

1 reference

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

21 January 2018

1 reference

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

21 January 2018

1 reference

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma

21 January 2018

1 reference

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

21 January 2018

1 reference

Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.

21 January 2018

1 reference

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors

21 January 2018

1 reference

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity

21 January 2018

1 reference

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

21 January 2018

1 reference

Autophagy in the Pathogenesis of Disease

21 January 2018

1 reference

Inhibition of histone deacetylase1 induces autophagy

21 January 2018

1 reference

Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation

21 January 2018

1 reference

Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.

21 January 2018

1 reference

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

21 January 2018

1 reference

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

21 January 2018

1 reference

Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line

21 January 2018

1 reference

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

21 January 2018

1 reference

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

21 January 2018

1 reference

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

21 January 2018

1 reference

Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines

21 January 2018

1 reference

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo

21 January 2018

1 reference

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series

21 January 2018

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy

21 January 2018

1 reference

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

21 January 2018

1 reference

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

21 January 2018

1 reference

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

21 January 2018

1 reference

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

21 January 2018

1 reference

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

21 January 2018

1 reference

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

21 January 2018

1 reference

12 December 2020

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

1 reference

12 December 2020

Histone deacetylase inhibitors induce mitotic slippage

1 reference

12 December 2020

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

1 reference

12 December 2020

Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.

1 reference

12 December 2020

Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.

1 reference

12 December 2020

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia

1 reference

12 December 2020

FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70

1 reference

12 December 2020

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

12 December 2020

Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

1 reference

12 December 2020

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

12 December 2020

Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents

1 reference

12 December 2020

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

12 December 2020

Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.

1 reference

12 December 2020

Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

1 reference

12 December 2020

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1 reference

12 December 2020

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

1 reference

12 December 2020

HDAC1 in axonal degeneration: A matter of subcellular localization

1 reference

12 December 2020

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

12 December 2020

The fundamental role of epigenetic events in cancer

1 reference

12 December 2020

Identifiers

DOI

10.2217/EPI.12.52

1 reference

release_7a5lwgk7i5hknhbhqz2wouy6ra

10 September 2017

Fatcat ID

0 references

PMC publication ID

7457146

0 references

1 reference